The forecast for antidepressant medicine sales in Canada indicates a slight decline from 2024 to 2028, with the value per capita projected to decrease from $31.2 in 2024 to $30.6 in 2028. This downward trend suggests a consistent annual contraction of sales. Year-on-year, a subtle negative growth is observed, reflecting a cautious market scenario. These variations highlight a shift from the previous patterns noted in 2023, where the market stood stronger.
Future trends to watch for include:
- Changes in healthcare policies that might affect drug pricing and sales.
- Innovation and new product launches in the antidepressant category.
- Shifts in public health initiatives focusing on mental wellness.
- Potential economic factors influencing purchasing power.
